MedTrace Logo

SARS-CoV-2 Pre-exposure Prophylaxis With Ivermectin Retrospective Cohort Study

NCT04832945 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 713

Last updated 2021-04-13

No results posted yet for this study

Summary

This observational study, a multicenter retrospective cohort database study, carried out in two medical centers, Centro Medico Bournigal (CMBO) in Puerto Plata and Centro Medico Punta Cana (CMPC) in Punta Cana, Dominican Republic, sought to determine whether Ivermectin, at a weekly orally dose of 0.2 mg/kg, is an effective pre-exposure prophylactic method (PrEP) for the spread of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), in the healthcare workers. The study began on June 29, 2020 and ended on July 26, 2020 (4 weeks).

Conditions

  • Covid19

Interventions

DRUG

Ivermectin 6 Mg Oral Tablet

Ivermectin weekly oral dose 0.2 mg/kg equivalent for 4 weeks

Sponsors & Collaborators

  • Grupo Rescue S.A.S República Dominicana

    lead NETWORK

Principal Investigators

  • Jose Morgenstern, MD · Grupo Rescue

  • Jose Natalio Redondo, MD · Grupo Rescue

  • Alvaro Olavarria, Data Analyst · Grupo Rescue

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-06-29
Primary Completion
2020-09-20
Completion
2021-04-10

Countries

  • Dominican Republic

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04832945 on ClinicalTrials.gov